Adnan Subei, DO, FAAN

A group of neuroimmunologists discuss how the updated McDonald criteria will shape neurologist training and highlight key barriers to implementation, including imaging access, resource limitations, and knowledge dissemination.

Panelists review emerging real-world and ECTRIMS data demonstrating that the updated McDonald criteria improve earlier MS diagnosis while maintaining diagnostic accuracy across diverse clinical settings.

Experts discuss how the updated McDonald criteria redefine radiologically isolated syndrome and explore the clinical, imaging, and access challenges of diagnosing and treating MS before symptom onset.

A panel of MS experts breaks down the most impactful updates to the 2024 McDonald criteria, highlighting how new biomarkers, imaging features, and diagnostic flexibility are reshaping earlier and more accurate MS diagnosis.

In this episode, Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

Neurologist Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.

In this episode, Adnan Subei, DO, FAAN, discusses siponimod, a selective S1P receptor modulator approved in 2019, its clinical advantages, efficacy, and how it may be useful for patients with multiple sclerosis.